131 results match your criteria Core Evidence[Journal]


Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.

Core Evid 2018 8;13:21-31. Epub 2018 Mar 8.

Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca, Ancona, Italy.

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy. Hence, there remains the need to develop new effective and well-tolerated therapies.

Aim: The objective of this article was to review the evidence for the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive treatment in adult patients with focal onset seizures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S142858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846310PMC
March 2018
9 Reads

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis.

Core Evid 2018 23;13:13-20. Epub 2018 Feb 23.

SKiN Centre for Dermatology, Peterborough, ON, Canada.

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant T2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/dupilumab-an-evidence-based-review
Publisher Site
http://dx.doi.org/10.2147/CE.S133661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826246PMC
February 2018
13 Reads

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.

Core Evid 2018 24;13:1-12. Epub 2018 Jan 24.

Division of Urology.

Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN) in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on current available clinical data.

Methods: This review was prospectively registered at the International Prospective Register of Systematic Reviews, PROSPERO (registration CRD42016049294). Electronic databases including MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched through December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S118670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790085PMC
January 2018
6 Reads

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.

Core Evid 2017 23;12:11-24. Epub 2017 Mar 23.

Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

Introduction: Hyperkalemia is a serious medical condition that often manifests in patients with chronic kidney disease and heart failure. Renin-angiotensin-aldosterone system inhibitors are known to improve outcomes in these disease states but can also cause drug-induced hyperkalemia. New therapeutic options exist for managing hyperkalemia in these patients which warrant evidence-based evaluation. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-utility-of-patiromer-sodi
Publisher Site
http://dx.doi.org/10.2147/CE.S129555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367739PMC
March 2017
38 Reads

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.

Core Evid 2017 15;12:1-10. Epub 2017 Mar 15.

Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; Harris Manchester College, University of Oxford, Oxford, United Kingdom.

Introduction: Deciding on an optimal medication choice for type 2 diabetes is often challenging, due to the increasing number of treatment options. Canagliflozin is a novel glucose-lowering agent belonging to sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Aim: The aim of this study was to examine and summarize the evidence based on the efficacy, safety, and cost-effectiveness of canagliflozin for type 2 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S109654DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358960PMC
March 2017
5 Reads

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.

Core Evid 2016 14;11:49-61. Epub 2016 Dec 14.

Department of Pharmacy, Federal University of Parana, Curitiba, Brazil.

Introduction: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S114094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167526PMC
December 2016
15 Reads

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy.

Core Evid 2016 14;11:37-47. Epub 2016 Oct 14.

Department of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.

Introduction: Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase.

Aim: The aim was to review the evidence underlying the use of imiglucerase in Gaucher disease type 1. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/imiglucerase-in-the-management-of-
Publisher Site
http://dx.doi.org/10.2147/CE.S93717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072572PMC
October 2016
8 Reads

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy.

Core Evid 2016 1;11:23-36. Epub 2016 Sep 1.

Medical Oncology Unit, University Hospital of Parma, Parma.

Introduction: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in which mTOR signaling pathway is implicated. Everolimus, an mTOR serine/threonine kinase inhibitor, represents a therapeutic option for the treatment of advanced RCC.

Aim: The objective of this article is to review the evidence for the treatment of metastatic RCC with everolimus. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/everolimus-in-the-management-of-me
Publisher Site
http://dx.doi.org/10.2147/CE.S98687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012611PMC
September 2016
19 Reads
5 Citations

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.

Core Evid 2016 1;11:11-22. Epub 2016 Jul 1.

Department of Thoracic Medicine and Laboratory of Molecular and Cellular Pneumonology, Interstitial Lung Disease Unit, University Hospital of Heraklion, Heraklion, Greece.

The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress regarding our knowledge on the pathogenesis of the disease together with the experience achieved after a series of negative trials has led to the development of two drugs for the treatment of IPF. Both pirfenidone and nintedanib can slow significantly the rate of disease progression. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/pirfenidone-in-the-treatment-of-id
Publisher Site
http://dx.doi.org/10.2147/CE.S76549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936814PMC
July 2016
19 Reads

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Core Evid 2016 5;11:1-10. Epub 2016 Apr 5.

Cardiovascular Pathophysiology and Imaging, Sapienza Università di Roma, Rome, Italy.

Background: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone (CLT).

Objective: To review pharmacology and clinical role of AZI monotherapy and AZI/CLT or AZI/amlodipine combination therapies for hypertension management.

Methods: PubMed, Embase, and Cochrane Library were searched using search terms " azilsartan", "chlorthalidone," "pharmacology," "pharmacokinetics," "pharmacodynamics," "pharmacoeconomics," and "cost-effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S81776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829189PMC
April 2016
7 Reads

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Core Evid 2015 2;10:99-109. Epub 2015 Nov 2.

College of Pharmacy, University of New Mexico, Albuquerque, NM, USA.

Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phos-phodiesterase-5 inhibitor that is administered once daily by mouth for the treatment of PAH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S58457DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636095PMC
November 2015
4 Reads

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Core Evid 2015 27;10:89-98. Epub 2015 Aug 27.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo.

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth factor, are also thought to contribute to the pathogenesis of pulmonary fibrosis. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/nintedanib-evidence-for-its-therape
Publisher Site
http://dx.doi.org/10.2147/CE.S82905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555978PMC
September 2015
15 Reads

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.

Core Evid 2015 21;10:75-87. Epub 2015 Aug 21.

Medical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Introduction: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron is effective in the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy (HEC and MEC, respectively). In addition, palonosetron has been the first and, at present, the only 5-HT3 receptor antagonist to have a specific indication for the prevention of delayed CINV associated with MEC. The unique pharmacology of this antagonist is thought to partly explain its improved efficacy against delayed symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S65555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554402PMC
September 2015
9 Reads

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.

Core Evid 2015 28;10:63-73. Epub 2015 May 28.

Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, Fresno, CA, USA.

Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S61441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422295PMC
May 2015
8 Reads

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.

Core Evid 2015 20;10:49-62. Epub 2015 Apr 20.

Department of Psychiatry, Columbia University, New York, NY, USA.

Introduction: It has clearly been demonstrated that depressive disorders constitute a major worldwide public health problem, with massive economic and quality-of-life consequences. Existing pharmacological treatments have limited efficacy, with only about a third of patients achieving remission on any one medication. Delayed onset of action and variable tolerability contribute to this limited efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S54075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408952PMC
May 2015
41 Reads

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.

Core Evid 2015 11;10:39-47. Epub 2015 Feb 11.

Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

The emergence of resistance to glycopeptide antibiotics such as vancomycin and teicoplanin among Gram-positive bacteria has spurred the search for second-generation drugs of this class. Oritavancin, a promising novel, second-generation, semisynthetic lipoglycopeptide, is distinguished by two mechanisms of action: inhibition of cell wall synthesis and disruption of the cell membrane. This dual mechanism of action has increased the activity of oritavancin against vancomycin-resistant Gram-positive bacteria compared to other glycopeptides. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/oritavancin-for-the-treatment-of-ac
Publisher Site
http://dx.doi.org/10.2147/CE.S51284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334198PMC
February 2015
7 Reads

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.

Core Evid 2015 9;10:11-21. Epub 2015 Jan 9.

Ambulatory Care Division, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.

Introduction: As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S55944DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295897PMC
February 2015
7 Reads

Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.

Core Evid 2015 13;10:23-38. Epub 2015 Jan 13.

Department of Internal Medicine, Virginia Commonwealth University, VA, USA ; VCU Massey Cancer Center, Richmond, VA, USA.

Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer therapy characterized by two or more of the following laboratory abnormalities: hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia, with resultant end-organ damage, eg, renal failure, seizures, or cardiac arrhythmias. High-risk patients include those with highly proliferative cancers and/or large tumor burdens, particularly in the setting of highly effective chemotherapy, among other risk factors. Before 2002, antihyperuricemic drug therapy was limited to allopurinol, a xanthine oxidase inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S54995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298251PMC
January 2015
15 Reads

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.

Core Evid 2015 18;10:1-10. Epub 2014 Dec 18.

Department of Medicine, Oregon Health and Science University, Portland, OR, USA.

Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S54712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279604PMC
January 2015
5 Reads

Luliconazole for the treatment of fungal infections: an evidence-based review.

Core Evid 2014 24;9:113-24. Epub 2014 Sep 24.

Department of Dermatology, Chacha Nehru Bal Chikitsalaya (Childrens Hospital), Delhi, India.

Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S49629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181444PMC
October 2014
80 Reads

Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Core Evid 2014 19;9:99-112. Epub 2014 Sep 19.

Department of Pediatric Pneumology, University Children's Hospital of Ruhr University Bochum at St Josef-Hospital, Bochum, Germany.

Chronic bacterial respiratory-tract infections are a major driving force in the pathogenesis of cystic fibrosis (CF) lung disease and promote chronic lung-function decline, destruction, and progression to respiratory failure at a premature age. Gram-negative bacteria colonizing the airways in CF are a major problem in CF therapy due to their tendency to develop a high degree of resistance to antibiotic agents over time. Pseudomonas aeruginosa is the dominating bacterial strain infecting the CF lung from early childhood on, and multiresistant strains frequently develop after years of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S64980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178503PMC
October 2014
8 Reads

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.

Core Evid 2014 17;9:81-7. Epub 2014 Jul 17.

Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA.

Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S48626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109634PMC
August 2014
5 Reads

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis.

Core Evid 2014 21;9:89-97. Epub 2014 Jul 21.

IBMC, Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal ; Biochemistry Laboratory, Biological Sciences Department, Faculty of Pharmacy (FFUP), University of Porto, Porto, Portugal.

Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/brodalumab-an-evidence-based-review
Publisher Site
http://dx.doi.org/10.2147/CE.S33940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112723PMC
August 2014
7 Reads

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Core Evid 2014 20;9:71-80. Epub 2014 Jun 20.

Department of Pharmacy, San Francisco VA Medical Center, San Francisco, CA, USA.

Pulmonary arterial hypertension (PAH) remains a progressive disease without a cure, despite the development of several treatment options over the past several decades. Its management strategy consists of the endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil), and prostacyclin analogs (epoprostenol, treprostinil, iloprost). Treprostinil, a stable prostacyclin analog, displays vasodilatory effects in the pulmonary vasculature, as well as antiplatelet aggregation properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S50607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073912PMC
July 2014
10 Reads

Development of cabozantinib for the treatment of prostate cancer.

Core Evid 2014 23;9:61-7. Epub 2014 Apr 23.

Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA.

Cabozantinib (XL184) is a multitargeted receptor tyrosine kinase with predominantly MET and vascular endothelial growth factor inhibition properties. It is currently approved by the US Food and Drug Administration for the treatment of progressive metastatic medullary thyroid cancer. The agent has a convenient once-daily oral dosing schedule and has demonstrated encouraging activity in metastatic castrate-resistant prostate cancer (CRPC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S48498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003147PMC
June 2014
9 Reads

Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential.

Core Evid 2014 21;9:51-9. Epub 2014 Mar 21.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S39363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968080PMC
June 2014
8 Reads

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.

Core Evid 2014 12;9:41-8. Epub 2014 Mar 12.

Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy.

Rheumatoid arthritis (RA) management has greatly improved with the development of biologic disease modifying antirheumatic drugs, but a proportion of patients do not improve despite the biologic drugs currently available. We need new biologic agents with novel mechanisms of action for the treatment of refractory patients. Recent evidence has shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) is involved in the pathogenesis of RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S39770DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958547PMC
June 2014
12 Reads

Micafungin: an evidence-based review of its place in therapy.

Core Evid 2014 25;9:27-39. Epub 2014 Feb 25.

Cooper Medical School of Rowan University, Camden, NJ, USA.

Invasive fungal infections have increased throughout the world. Many of these infections occur in patients with multiple comorbidities who are receiving medications with the potential for interactions with antifungal therapy that could lead to renal and hepatic dysfunction. The second marketed echinocandin, micafungin, was approved in 2005 for the treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S36304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940642PMC
June 2014
8 Reads

Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Core Evid 2014 24;9:13-25. Epub 2014 Jan 24.

Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, MB, Canada ; Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada.

Avibactam (NXL104, AVE1330A) is a semi-synthetic, non-β-lactam, β-lactamase inhibitor that is active against Ambler class A, class C, and some class D serine β-lactamases. In this review, we summarize the in vitro data, pharmacology, mechanisms of action and resistance, and clinical trial data relating to the use of this agent combined with ceftazidime for the treatment of Gram-negative bacterial infections. The addition of avibactam to ceftazidime improves its in vitro activity against Enterobacteriaceae and Pseudomonas aeruginosa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S40698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908787PMC
June 2014
41 Reads

Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.

Core Evid 2014 6;9:1-11. Epub 2014 Jan 6.

Roche do Brasil, São Paulo, Brazil.

Objective: To perform a systematic review and meta-analysis of randomized controlled trials that compared the efficacy of targeted therapy to conventional chemotherapy (CT) in patients with metastatic triple-negative breast cancer (TNBC).

Methods: Several databases were searched, including Medline, Embase, LILACS, and CENTRAL. The primary end point was progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S52197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891489PMC
June 2014
10 Reads

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis.

Core Evid 2013 30;8:69-78. Epub 2013 Sep 30.

Evidencias Scientific information, Campinas, São Paulo, Brazil.

Background: This paper reports a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in human epidermal growth factor receptor 2-overexpressing (HER-2+) locally advanced or metastatic breast cancer.

Methods: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were progression-free survival and overall survival. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/lapatinib-plus-chemotherapy-or-endo
Publisher Site
http://dx.doi.org/10.2147/CE.S50474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793631PMC
June 2014
9 Reads

Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Core Evid 2013 25;8:57-67. Epub 2013 Sep 25.

Klinik für Anaesthesiologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany ; Department of Anesthesia, Massachusetts General Hospital, Boston, MA, USA.

Sugammadex is the first clinical representative of a new class of drugs called selective relaxant binding agents. It has revolutionized the way anesthesiologists think about drug reversal. Sugammadex selectively binds rocuronium or vecuronium, thereby reversing their neuromuscular blocking action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S35675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789633PMC
June 2014
9 Reads

Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia.

Core Evid 2013 11;8:47-56. Epub 2013 Jul 11.

Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA.

Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S36744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712664PMC
July 2013
7 Reads

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.

Core Evid 2013 16;8:37-45. Epub 2013 May 16.

H Lee Moffitt Cancer and Research Institute, Division of Malignant Hematology, and University of South Florida, Tampa, FL, USA.

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable course, and remains an incurable disease. Frequent relapses and eventual resistance to fludarabine characterize symptomatic CLL and portends a dismal prognosis for patients. Growing evidence has shown that signaling pathways such as the B cell receptor and NFkB are implicated in the survival and proliferation of the CLL cells which are ultimately associated with persistence of the disease. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/ibrutinib-an-evidence-based-review-
Publisher Site
http://dx.doi.org/10.2147/CE.S34068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662532PMC
May 2013
8 Reads
7 Citations

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.

Core Evid 2013 4;8:27-35. Epub 2013 Apr 4.

Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA.

Introduction: Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring AR amplification or overexpression. Enzalutamide has demonstrated significant activity in men with metastatic CRPC.

Aims: To update the evidence and provide an overview of the available data on enzalutamide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S34747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622394PMC
April 2013
5 Reads

Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis.

Core Evid 2013 7;8:1-13. Epub 2013 Mar 7.

CoBEU and Evidencias - CoBEU, Brazil.

Background: The purpose of this work was to conduct a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy and side effect profile of hypofractionated versus conventional external-beam radiation therapy for prostate cancer.

Methods: Several databases were searched, including Medline, EmBase, LiLACS, and Central. The endpoints were freedom from biochemical failure and side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S41178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596128PMC
March 2013
13 Reads

An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies.

Core Evid 2013 14;8:15-26. Epub 2013 Mar 14.

Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada.

Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anticancer therapeutic for hematological malignancies and solid tumors. Obatoclax was developed as a pan-inhibitor of antiapoptotic members of the B cell chronic lymphocytic leukemia/lymphoma 2 (BCL-2) family of proteins, which control the intrinsic or mitochondrial pathway of apoptosis. Resistance to apoptosis through dysregulation of BCL-2 family members is commonly observed in hematological malignancies, and can be linked to therapeutic resistance and poor clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S42568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601645PMC
March 2013
5 Reads

An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Core Evid 2012 11;7:131-43. Epub 2012 Dec 11.

Division of Infectious Diseases, Akron General Medical Center, Akron, OH, USA.

Methicillin-resistant Staphylococcus aureus (MRSA), including community-associated and hospital-associated strains, is a major cause of human morbidity and mortality. Treatment options have become limited due to the emergence of MRSA strains with decreased sensitivity to vancomycin, which has long been the first-line therapy for serious infections. This has prompted the search for novel antibiotics that are efficacious against MRSA. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/an-evidence-based-review-of-linezol
Publisher Site
http://dx.doi.org/10.2147/CE.S33430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526863PMC
December 2012
10 Reads

Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.

Core Evid 2012 26;7:115-30. Epub 2012 Oct 26.

Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Oncology Center Johns Hopkins University, Baltimore, MD, USA.

The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine which slowly degrades to release carmustine and protects it from exposure to water with resultant hydrolysis until the time of release. The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/polifeprosan-20-385-carmustine-slow
Publisher Site
http://dx.doi.org/10.2147/CE.S23244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484478PMC
November 2012
6 Reads

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Core Evid 2012 27;7:105-14. Epub 2012 Sep 27.

Département d'Anesthésie Réanimation, Centre de Référence des Angioedèmes à Bradykinine, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon.

Introduction: Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.

Aims: To update the evidence and provide an overview of the available data on icatibant.

Evidence Review: Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S24743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467996PMC
October 2012
12 Reads
5 Citations

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.

Core Evid 2012 14;7:93-103. Epub 2012 Sep 14.

Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA.

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and is universally fatal. Despite surgical resection, radiotherapy, and systemic chemotherapy, the median overall survival is less than 15 months. As current therapies are not tumor-specific, treatment commonly results in toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S29001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459544PMC
October 2012
11 Reads

Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency.

Core Evid 2012 19;7:77-91. Epub 2012 Jul 19.

Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado.

Pancreatic exocrine insufficiency (PEI) is often observed in patients with pancreatic diseases, including chronic pancreatitis, cystic fibrosis, and tumors, or after surgical resection. PEI often results in malnutrition, weight loss and steatorrhea, which together increase the risk of morbidity and mortality. Therefore, nutritional interventions, such as low-fat diets and pancreatic enzyme replacement therapy (PERT), are needed to improve the clinical symptoms, and to address the pathophysiology of pancreatic exocrine insufficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S26705DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426252PMC
October 2012
6 Reads

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action.

Core Evid 2012 12;7:61-75. Epub 2012 Jul 12.

University Tennessee College of Medicine, Chattanooga, TN, USA.

Colesevelam hydrochloride is a molecularly engineered, second-generation bile acid sequestrant demonstrating enhanced specificity for bile acids which has been approved for use as adjunctive therapy to diet and exercise as monotherapy or in combination with a β-hydroxymethylglutaryl-coenzyme A reductase inhibitor for the reduction of elevated low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. It is also the only lipid-lowering agent currently available in the United States which has been approved for use as adjunctive therapy in patients with type 2 diabetes mellitus whose glycemia remains inadequately controlled on therapy with metformin, sulfonylurea, or insulin. With the recent emphasis upon drug safety by the Food and Drug Administration and various consumer agencies, it is fitting that the role of nonsystemic lipid-lowering therapies such as bile acid sequestrants - with nearly 90 years of in-class, clinically safe experience - should be reexamined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S26725DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426253PMC
October 2012
8 Reads

An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.

Core Evid 2012 9;7:49-59. Epub 2012 Jul 9.

Chief Cardiology Division, VACCHCS/UCSF, Fresno, CA, USA.

Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It is associated with cardioembolic complications, particularly strokes, resulting in severe functional deficit or death. AF patients are first stratified into low, intermediate, and high risk for thromboembolic events using the CHADS(2) and CHA(2)DS(2)-VASc score systems. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/an-evidence-based-review-of-apixaba
Publisher Site
http://dx.doi.org/10.2147/CE.S25637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402013PMC
October 2012
7 Reads

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation.

Core Evid 2012 25;7:39-47. Epub 2012 Jun 25.

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Both irritable bowel syndrome (IBS), characterized by chronic and recurrent abdominal pain and altered bowel habits, and functional constipation are highly prevalent gastrointestinal problems for which many patients seek medical advice. A diverse number of treatment approaches are currently recommended to treat persons with chronic constipation as well as patients with IBS in which constipation is the main gastrointestinal symptom (IBS-C). These approaches have had somewhat limited success, and many patients remain dissatisfied with available therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S25240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396047PMC
October 2012
10 Reads

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

Authors:
Klaus G Parhofer

Core Evid 2012 31;7:29-38. Epub 2012 May 31.

Medical Department II, Grosshadern, University Munich, Munich, Germany.

Familial hypercholesterolemia (FH) is an autosomal-dominant inherited disease with a prevalence of one in 500 (heterozygous) to one in 1,000,000 (homozygous). Mutations of the low-density lipoprotein (LDL) receptor gene, the apolipoprotein B100 gene, or the PCSK9 gene may be responsible for the disease. The resulting LDL hypercholesterolemia results in premature atherosclerosis as early as childhood (homozygous FH) or in adulthood (heterozygous FH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S25239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373191PMC
October 2012
17 Reads

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.

Authors:
Edward C Chao

Core Evid 2012 1;7:21-8. Epub 2012 Jun 1.

University of California, San Diego and VA San Diego Healthcare System, San Diego, CA, USA.

Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the urine (glucosuria) has transformed what was once solely regarded as an adverse facet of diabetes into a potential novel therapeutic strategy. Glucosuria leads to weight loss, due to a reduction in calories, which is thought to rehabilitate insulin sensitivity, at least partially. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S16359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373192PMC
October 2012
5 Reads

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease.

Authors:
Carla Em Hollak

Core Evid 2012 4;7:15-20. Epub 2012 May 4.

Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.

Gaucher disease is an inherited lysosomal storage disorder, characterized by deficient activity of glucocerebrosidase leading to storage of glucocerebroside in tissue macrophages. Type I disease, the most prevalent form, lacks central nervous system involvement but presents primarily with variable degrees of hepatosplenomegaly, cytopenia, and bone disease. Intravenous enzyme replacement therapy can reverse these manifestations. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/an-evidence-based-review-of-the-pot
Publisher Site
http://dx.doi.org/10.2147/CE.S20201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363131PMC
October 2012
7 Reads

Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

Core Evid 2012 19;7:1-14. Epub 2012 Jan 19.

Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast, Ireland.

Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S13841DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273363PMC
October 2012
10 Reads

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.

Core Evid 2011 8;6:67-79. Epub 2011 Sep 8.

University of Birmingham and BioMedical Research Centre, Heart of England National Health Service Foundation Trust, Birmingham, UK.

Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic control with little or no hypoglycemia and weight loss. Phase II trials have shown that lixisenatide 20 μg once daily restores first-phase insulin release in patients with type 2 diabetes and improves the second-phase insulin response. Administered once or twice daily for 4 weeks, it significantly reduced postprandial and fasting blood glucose levels, and glycosylated hemoglobin (HbA(1c)). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CE.S15525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195668PMC
November 2011
6 Reads